



# Why Compromise on Tissue Treatments?

While absent with the Carpentier-Edwards PERIMOUNT bioprostheses with XenoLogiX treatment, pannus, vegetation, leaflet retraction or calcific deposits were exhibited in *all* Mosaic bioprostheses with AOA treatment in the sheep model.<sup>1\*</sup>

### Large Animal Model (Sheep)

	Pannus	Vegetation	Leaflet Retraction	Calcific Deposits
S.A.V. (n=5)	0%	0%	40%	20%
Hancock II (n=5)	0%	0%	40%	20%
Mosaic (n=5)	20%	20%	40%	40%
<b>PERIMOUNT (n=6)</b>	<b>0%</b>	<b>0%</b>	<b>0%</b>	<b>0%</b>



Explanted PERIMOUNT Bioprosthesis



Explanted Stented Porcine Bioprosthesis

\*No clinical data are available which evaluate the long-term impact of the XenoLogiX treatment or AOA treatment in patients.




Edwards  
LIFESCIENCES



# Compromise on Tissue Treatments?

## Comparative Calcium Content of Bioprosthetic Valve Leaflet Tissue<sup>2\*</sup>



*In the rat subcutaneous model, PERIMOUNT valves calcified 87% less than Mosaic valves.<sup>2</sup>*

\*No clinical data are available which evaluate the long-term impact of the XenoLogiX treatment or AOA treatment in patients.

**References:**

1. In vivo evaluation of bioprosthetic mitral valves in the juvenile sheep model. Data on file at Edwards Lifesciences.
2. Cunanan, et al. Tissue characterization and calcification potential of commercial bioprosthetic heart valves. Ann Thorac Surg 2001;71:S417-21.

Caution: Federal (USA) law restricts this device to sale by or on the order of a physician. See instructions for use for full prescribing information.

Edwards Lifesciences, Edwards and the stylized E logo are trademarks of Edwards Lifesciences Corporation. Carpentier-Edwards and PERIMOUNT are trademarks of Edwards Lifesciences Corporation and are registered in the U.S. Patent and Trademark office.

Hancock and Mosaic are registered trademarks of Medtronic, Inc.

©2003 Edwards Lifesciences LLC  
All rights reserved. AR00342



**Edwards Lifesciences**